Development of a bispecific antibody tetramerized through hetero-associating peptides

The FEBS Journal
Tomohiro OsakiTakeshi Nakanishi

Abstract

The specific assembly of self-associating peptides can be useful in building a functional antibody complex from small antibody fragments. We have focused on the exceedingly specific heterotetrameric assembly of Lin-2 and Lin-7 (L27) domains, which work as protein-protein interaction modules in many scaffold proteins. Here, we describe a novel method for constructing a highly functional antibody based on the hetero-association of L27 domains. In this study, we used a bacterial expression system to produce a bispecific antibody that was heterotetramerized through L27 domains and that targeted both epidermal growth factor receptor (EGFR) and Fcγ receptor III (FcγRIII or CD16). Gel electrophoresis, mass spectrometry and gel filtration analyses revealed that the constructed recombinant antibody was a disulfide-linked heterotetramer. The tetramerized antibody bound to EGFR and CD16 simultaneously, according to results from flow cytometry and surface plasmon resonance spectroscopy, respectively. Furthermore, we demonstrated that the bispecific antibody showed cytotoxic activity against EGFR-expressing tumor cells by using CD16-positive lymphocytes as effectors, and its cytotoxicity was comparable to that of a commercial therapeutic an...Continue Reading

References

Jan 1, 1986·Methods in Enzymology·M R SureshC Milstein
Jun 29, 2000·Trends in Biochemical Sciences·T DoerksB Margolis
Oct 29, 2000·The Journal of Biological Chemistry·K Els ConrathS Muyldermans
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Nov 25, 2003·Nature Biotechnology·Sergey M DeyevAndreas Plückthun
May 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Wei FengMingjie Zhang
Sep 10, 2005·Nature Biotechnology·Philipp Holliger, Peter J Hudson
Apr 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Edmund A RossiChien-Hsing Chang
Jun 2, 2006·Cancer Immunology, Immunotherapy : CII·Rob C RooversPaul M P van Bergen en Henegouwen
Sep 12, 2006·The Journal of Biological Chemistry·Susanne KubetzkoAndreas Plückthun
Dec 13, 2007·Protein Engineering, Design & Selection : PEDS·Ghislaine BeharDaniel Baty
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Feb 17, 2009·Expert Opinion on Biological Therapy·Dimiter V Tassev, Nai-Kong V Cheung
Aug 28, 2009·Journal of Biochemistry·Takuya ShishidoAkihiko Kondo
Sep 1, 2009·Cancer Letters·Andrea BellJianbing Zhang
Dec 18, 2009·The FEBS Journal·Ryutaro AsanoIzumi Kumagai
Mar 10, 2010·Immunology and Cell Biology·Xuekai ZhuBin Gao
May 8, 2010·Trends in Biotechnology·Angel M CuestaLuis Alvarez-Vallina
Dec 25, 2010·British Journal of Pharmacology·Jamie CampbellMatthew A Sleeman
Apr 23, 2011·Drug Discovery Today·Swati ChoudharyRama S Verma
Jan 1, 2011·Annual Review of Chemical and Biomolecular Engineering·Eric T Boder, Wei Jiang
Sep 19, 2012·Protein Engineering, Design & Selection : PEDS·Oliver SeifertRoland E Kontermann
Dec 6, 2012·Journal of the American Chemical Society·Stephanie A KazaneVaughn V Smider
Aug 31, 2013·Clinical Pharmacology : Advances and Applications·Thomas List, Dario Neri
Oct 19, 2013·International Journal of Cancer. Journal International Du Cancer·Yusuke NakadateFumiaki Koizumi
Sep 10, 2014·Critical Reviews in Oncology/hematology·Roeland LamerisHans J van der Vliet

❮ Previous
Next ❯

Citations

Feb 24, 2018·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Tomohiro OsakiMasaya Kitamura
Sep 22, 2017·Journal of Hematology & Oncology·Shengnan YuKongming Wu
Dec 2, 2020·International Journal of Molecular Sciences·Atsushi KuwaharaRyutaro Asano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.